We serve Chemical Name:3-amino-1H-quinazoline-2,4-dione CAS:30386-01-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:3-amino-1H-quinazoline-2,4-dione
CAS.NO:30386-01-7
Synonyms:3-amino-1,2,3,4-tetrahydro-2,4-quinazolinedione;3-Amino-1H-chinazolin-2,4-dion;3-amino-2,4-dioxo-1,2,3,4-tetrahydroquinazoline
Molecular Formula:C8H7N3O2
Molecular Weight:177.16000
HS Code:2933990090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:1.429g/cm3
Index of Refraction:1.638
PSA:81.14000
Exact Mass:177.05400
LogP:0.39710
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 3-amino-1,2,3,4-tetrahydro-2,4-quinazolinedione chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-amino-2,4-dioxo-1,2,3,4-tetrahydroquinazoline physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-Amino-1H-chinazolin-2,4-dion Use and application,3-amino-2,4-dioxo-1,2,3,4-tetrahydroquinazoline technical grade,usp/ep/jp grade.
Related News: Complete the research and development of APIs and intermediates, design new patented process routes, and explore new crystal forms. 3-amino-1H-quinazoline-2,4-dione manufacturer Under the terms of this agreement, Inceptua will support Onconova through the pre-approval provision of intravenous rigosertib initially into a number of countries including: Australia, Denmark, Finland, France, Ireland, Italy, the Netherlands, Portugal, South Africa, Spain, and the UK. 3-amino-1H-quinazoline-2,4-dione supplier The new rules started Saturday — however if you’re an Australian citizen, permanent resident or their immediate family, or an aircrew member who has been using appropriate protective equipment, you’re exempt. 3-amino-1H-quinazoline-2,4-dione vendor The Company��s immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. 3-amino-1H-quinazoline-2,4-dione factory Under the terms of this agreement, Inceptua will support Onconova through the pre-approval provision of intravenous rigosertib initially into a number of countries including: Australia, Denmark, Finland, France, Ireland, Italy, the Netherlands, Portugal, South Africa, Spain, and the UK.
